New study Equazen® mumomega®
New study Equazen® mumomega®
SFI Health is happy to announce the first investigation that shows measurable anatomical changes (MRI scans) in the brain of infants in response to maternal supplementation with fatty acids using Equazen® mumomega®. The clinical trial was conducted at the Chelsea & Westminster Hospital London, UK and published in the scientific journal Prostaglandins Leukotrienes Essential Fatty Acids (PLEFA 138 (2018) 6-13). This is the first study to show maternal BSFA supplementation enhances newborn infant’s brain size and suggests differential sex sensitivity of fetal brains to pregnancy BSFA status.